October 30, 2024
2 min watch
Save
VIDEO: Longer follow-up may increase benefits of ribociclib in some patients with breast cancer
Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, discussed the long-term follow-up data of 4-year outcomes from the NATALEE trial.
The data, presented at ESMO Congress, showed the benefit seen after patients with hormone receptor-positive, HER2-negative breast cancer were off ribociclib (Kisqali, Novartis), Tolaney told Healio in a video interview.
“I do think this 4-year data was really important for us to see so that we can see that the benefits of ribociclib are increasing with longer follow-up,” Tolaney said.
Reference:
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Tolaney reports numerous ties to industry.